06/22/22 8:00 AMNasdaq : ALGS clinical triallow floatAligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for CAM Drug Candidate ALG-000184, First Clinical Data for NASH Drug Candidate ALG-055009 and Nonclinical Data in Other Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital International Liver Congress™ 2022- Similar significant reductions of hepatitis B virus (HBV) DNA and HBV RNA observed following 28 days of daily oral ALG-000184 dosing, regardless of HBeAg status, across first four dosing chronic hepatitis B (CHB) patient cohorts -In the first clinical data presentation from our NASH program,RHEA-AIneutral
06/06/22 8:00 AMNasdaq : ALGS conferenceslow floatAligos Therapeutics to Participate in Metropolitan AntiViral Drug Accelerator, Recipient of NIH and NIAID Grant to Develop Therapeutics Against Coronaviruses and Pathogens of Pandemic PotentialAligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company willRHEA-AIneutral
05/23/22 4:05 PMNasdaq : ALGS conferenceslow floatAligos Therapeutics to Present at the Jefferies 2022 Healthcare ConferenceAligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D.,RHEA-AIneutral
05/04/22 4:05 PMNasdaq : ALGS earningslow floatAligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial ResultsAligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress andRHEA-AIneutral
05/03/22 8:00 AMNasdaq : ALGS conferencesclinical triallow floatAligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s International Liver Congress™ 2022Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to addressRHEA-AIneutral
04/27/22 4:05 PMNasdaq : ALGS low float Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022 Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report theRHEA-AIneutral
04/04/22 8:00 AMNasdaq : ALGS covid-19low floatAligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stageRHEA-AIneutral
03/22/22 8:00 AMNasdaq : ALGS low floatAligos Discontinues Development of its Antisense Oligonucleotide Drug Candidate ALG-020572 in Subjects with Chronic Hepatitis B and Pivots Internal Strategic Emphasis to its Small Molecule PortfolioDosing in the first cohort discontinued after multiple reports of ALT flares suggestive of drug-induced liver toxicity Funds will be redirected to support ongoing clinical programs, including ALG-000184 (Class-II CAM for CHB) and ALG-055009 (THR- agonist for NASH), and to accelerate internal oralRHEA-AIneutral
03/10/22 4:05 PMNasdaq : ALGS earningslow floatAligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business HighlightsCAM (ALG-000184) continues to demonstrate best in class potential in Phase 1b ASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1 st cohort fully enrolled siRNA (ALG-125755) progressing on track through Phase 1 enabling nonclinical studies THR-β (ALG-055009)RHEA-AIneutral
03/02/22 4:05 PMNasdaq : ALGS low floatAligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report theRHEA-AIneutral